Testosterone Therapy in Heart Failure

• Status: Withdrawn
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to evaluate whether benefits of topical testosterone on symptoms and function of male HF patients, and its effects on rehospitalization rates and quality of life.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cedars-Sinai Medical Center
• Collaborator: Abbott
• Treatments: Methyltestosterone; Testosterone; Testosterone 17 beta-cypionate; Testosterone enanthate; Testosterone undecanoate

Criteria

Inclusion Criteria:

• male

• NYHA class II-IV Heart Failure

• age > 35 < 80

• total testosterone level of <5 ng/ml

Exclusion Criteria:

• elevated prostate specific antigen

• elevated total or free testosterone level

• prostate cancer or evidence of symptomatic prostatism

• untreated prolactinemia or history of breast cancer